Mazindol: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Mazindol== | |||
'''Mazindol''' is a [[ | [[File:Mazindol.svg|thumb|right|Chemical structure of Mazindol]] | ||
'''Mazindol''' is a [[stimulant]] medication that is primarily used as an [[anorectic]] agent to aid in weight loss. It functions by suppressing appetite and is chemically related to the [[tricyclic antidepressants]]. Mazindol is not an [[amphetamine]], but it has similar effects on the central nervous system. | |||
==Pharmacology== | ==Pharmacology== | ||
Mazindol acts as a [[monoamine reuptake inhibitor]], primarily affecting the | |||
Mazindol acts as a [[monoamine reuptake inhibitor]], primarily affecting the [[neurotransmitters]] [[norepinephrine]] and [[dopamine]]. By inhibiting the reuptake of these neurotransmitters, mazindol increases their levels in the synaptic cleft, leading to enhanced stimulation of the [[central nervous system]]. This action results in decreased appetite and increased energy expenditure, which are beneficial for weight loss. | |||
[[File:Mazindol3Dan.gif|thumb|left|3D animation of Mazindol molecule]] | |||
==Medical Uses== | ==Medical Uses== | ||
Mazindol is prescribed for short-term management of | |||
Mazindol is prescribed for the short-term management of [[obesity]] in conjunction with a [[calorie-restricted diet]] and [[exercise]]. It is typically used in patients who have not responded adequately to other weight loss interventions. The medication is usually prescribed for a few weeks, as its effectiveness tends to decrease with prolonged use. | |||
==Side Effects== | ==Side Effects== | ||
Common side effects of mazindol include [[dry mouth]], [[insomnia]], [[nervousness]], and [[constipation]]. More serious side effects can include [[hypertension]], [[tachycardia]], and [[palpitations]]. Due to its stimulant properties, mazindol has the potential for abuse and dependence, although this risk is lower compared to amphetamines. | |||
== | ==Chemistry== | ||
Mazindol is | |||
Mazindol is a [[tetracyclic compound]] with a unique chemical structure that distinguishes it from other anorectic agents. Its chemical formula is C16H13ClN2O, and it has a molecular weight of 284.74 g/mol. | |||
[[File:Chemrat_Mazindol.svg|thumb|right|Mazindol chemical structure with rat pharmacophore]] | |||
==History== | ==History== | ||
Mazindol was first introduced in the 1970s | |||
Mazindol was first introduced in the 1970s as an appetite suppressant. It was marketed under various brand names, including [[Sanorex]] and [[Mazanor]]. Over time, its use has declined due to the development of newer weight loss medications and concerns about its side effects and potential for abuse. | |||
==Regulation== | ==Regulation== | ||
In many countries, mazindol is classified as a controlled substance due to its potential for abuse. Its availability is restricted, and it is typically prescribed only when other weight loss strategies have failed. | |||
==Research== | ==Research== | ||
Recent studies have explored the potential use of mazindol in treating [[narcolepsy]] and [[attention deficit hyperactivity disorder]] (ADHD), given its effects on dopamine and norepinephrine. However, more research is needed to establish its efficacy and safety for these indications. | |||
[[File:Mazindol_Tautomer_Pharmacophore.svg|thumb|left|Mazindol tautomer pharmacophore]] | |||
== | ==Related Pages== | ||
* [[Obesity]] | |||
* [ | * [[Stimulant]] | ||
* [ | * [[Appetite suppressant]] | ||
* [[Monoamine reuptake inhibitor]] | |||
[[Category:Anorectics]] | [[Category:Anorectics]] | ||
[[Category: | [[Category:Stimulants]] | ||
[[Category: | [[Category:Weight loss drugs]] | ||
Latest revision as of 11:08, 23 March 2025
Mazindol[edit]
Mazindol is a stimulant medication that is primarily used as an anorectic agent to aid in weight loss. It functions by suppressing appetite and is chemically related to the tricyclic antidepressants. Mazindol is not an amphetamine, but it has similar effects on the central nervous system.
Pharmacology[edit]
Mazindol acts as a monoamine reuptake inhibitor, primarily affecting the neurotransmitters norepinephrine and dopamine. By inhibiting the reuptake of these neurotransmitters, mazindol increases their levels in the synaptic cleft, leading to enhanced stimulation of the central nervous system. This action results in decreased appetite and increased energy expenditure, which are beneficial for weight loss.
Medical Uses[edit]
Mazindol is prescribed for the short-term management of obesity in conjunction with a calorie-restricted diet and exercise. It is typically used in patients who have not responded adequately to other weight loss interventions. The medication is usually prescribed for a few weeks, as its effectiveness tends to decrease with prolonged use.
Side Effects[edit]
Common side effects of mazindol include dry mouth, insomnia, nervousness, and constipation. More serious side effects can include hypertension, tachycardia, and palpitations. Due to its stimulant properties, mazindol has the potential for abuse and dependence, although this risk is lower compared to amphetamines.
Chemistry[edit]
Mazindol is a tetracyclic compound with a unique chemical structure that distinguishes it from other anorectic agents. Its chemical formula is C16H13ClN2O, and it has a molecular weight of 284.74 g/mol.
History[edit]
Mazindol was first introduced in the 1970s as an appetite suppressant. It was marketed under various brand names, including Sanorex and Mazanor. Over time, its use has declined due to the development of newer weight loss medications and concerns about its side effects and potential for abuse.
Regulation[edit]
In many countries, mazindol is classified as a controlled substance due to its potential for abuse. Its availability is restricted, and it is typically prescribed only when other weight loss strategies have failed.
Research[edit]
Recent studies have explored the potential use of mazindol in treating narcolepsy and attention deficit hyperactivity disorder (ADHD), given its effects on dopamine and norepinephrine. However, more research is needed to establish its efficacy and safety for these indications.
